^

News and Publications

Section Menu  

 

FDA approves Novartis plant for production of Pluvicto

April 24, 2023

Novartis announced on April 21, 2023, that they received approval by the U.S. Food and Drug Administration (FDA) to begin supplying Pluvicto for U.S. commercial use from their manufacturing facility in Millburn, NJ. Capacity should increase through the second half of the year, helping to ensure stable, reliable supply to patients. Last month, ASTRO expressed concern to the FDA that without this U.S.-based facility, Novartis was unable to meet demand, and patients were either not receiving their full treatment, or their treatment was being delayed.

Copyright © 2024 American Society for Radiation Oncology